Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19 : a nationwide observational study of 8075 participants
Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved..
Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19. We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. Of 8075 patients with complete discharge data on 24 May 2020 and diagnosed before 1 May 2020, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio (aHR) = 0.684, 95% confidence interval (CI) 0.617-0.758]. Compared with the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤5 days (n = 3975) and >5 days (n = 3487) after symptom onset [aHR = 0.701 (95% CI 0.617-0.796) and aHR = 0.647 (95% CI 0.525-0.797), respectively]. Compared with supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after symptom onset.
| Errataetall: |
CommentIn: Int J Antimicrob Agents. 2021 Apr;57(4):106308. - PMID 33609717 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
International journal of antimicrobial agents - 56(2020), 4 vom: 01. Okt., Seite 106144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Catteau, Lucy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 01.10.2020 Date Revised 19.12.2022 published: Print-Electronic CommentIn: Int J Antimicrob Agents. 2021 Apr;57(4):106308. - PMID 33609717 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijantimicag.2020.106144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314269223 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314269223 | ||
| 003 | DE-627 | ||
| 005 | 20231225152351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijantimicag.2020.106144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314269223 | ||
| 035 | |a (NLM)32853673 | ||
| 035 | |a (PII)S0924-8579(20)30342-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Catteau, Lucy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19 |b a nationwide observational study of 8075 participants |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.10.2020 | ||
| 500 | |a Date Revised 19.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Int J Antimicrob Agents. 2021 Apr;57(4):106308. - PMID 33609717 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. | ||
| 520 | |a Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19. We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. Of 8075 patients with complete discharge data on 24 May 2020 and diagnosed before 1 May 2020, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio (aHR) = 0.684, 95% confidence interval (CI) 0.617-0.758]. Compared with the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤5 days (n = 3975) and >5 days (n = 3487) after symptom onset [aHR = 0.701 (95% CI 0.617-0.796) and aHR = 0.647 (95% CI 0.525-0.797), respectively]. Compared with supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after symptom onset | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Observational study | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Dauby, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Montourcy, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Bottieau, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Hautekiet, Joris |e verfasserin |4 aut | |
| 700 | 1 | |a Goetghebeur, Els |e verfasserin |4 aut | |
| 700 | 1 | |a van Ierssel, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Duysburgh, Els |e verfasserin |4 aut | |
| 700 | 1 | |a Van Oyen, Herman |e verfasserin |4 aut | |
| 700 | 1 | |a Wyndham-Thomas, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Van Beckhoven, Dominique |e verfasserin |4 aut | |
| 700 | 0 | |a Belgian Collaborative Group on COVID-19 Hospital Surveillance |e verfasserin |4 aut | |
| 700 | 1 | |a Bafort, Kristof |e investigator |4 oth | |
| 700 | 1 | |a Belkhir, Leïla |e investigator |4 oth | |
| 700 | 1 | |a Bossuyt, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Caprasse, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Colombie, Vincent |e investigator |4 oth | |
| 700 | 1 | |a De Munter, Paul |e investigator |4 oth | |
| 700 | 1 | |a Deblonde, Jessika |e investigator |4 oth | |
| 700 | 1 | |a Delmarcelle, Didier |e investigator |4 oth | |
| 700 | 1 | |a Delvallee, Mélanie |e investigator |4 oth | |
| 700 | 1 | |a Demeester, Rémy |e investigator |4 oth | |
| 700 | 1 | |a Dugernier, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Holemans, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Kerzmann, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Yves Machurot, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Minette, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Minon, Jean-Marc |e investigator |4 oth | |
| 700 | 1 | |a Mokrane, Saphia |e investigator |4 oth | |
| 700 | 1 | |a Nachtergal, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Noirhomme, Séverine |e investigator |4 oth | |
| 700 | 1 | |a Piérard, Denis |e investigator |4 oth | |
| 700 | 1 | |a Rossi, Camelia |e investigator |4 oth | |
| 700 | 1 | |a Schirvel, Carole |e investigator |4 oth | |
| 700 | 1 | |a Sermijn, Erica |e investigator |4 oth | |
| 700 | 1 | |a Staelens, Frank |e investigator |4 oth | |
| 700 | 1 | |a Triest, Filip |e investigator |4 oth | |
| 700 | 1 | |a Goethem, Nina Van |e investigator |4 oth | |
| 700 | 1 | |a Praet, Jens Van |e investigator |4 oth | |
| 700 | 1 | |a Vanhoenacker, Anke |e investigator |4 oth | |
| 700 | 1 | |a Verstraete, Roeland |e investigator |4 oth | |
| 700 | 1 | |a Willems, Elise |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of antimicrobial agents |d 1991 |g 56(2020), 4 vom: 01. Okt., Seite 106144 |w (DE-627)NLM090678974 |x 1872-7913 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2020 |g number:4 |g day:01 |g month:10 |g pages:106144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijantimicag.2020.106144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2020 |e 4 |b 01 |c 10 |h 106144 | ||